Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Jakinibs

Upadacitinib Safety Similar to Other Jakinibs for RA

Lisa Rapaport  |  November 16, 2020

(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…

Filed under:Drug Updates Tagged with:JAK inhibitorsjakinibRheumatoid Arthritis (RA)upadacitinib

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

Jason Liebowitz, MD, FACR  |  November 9, 2020

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

Filed under:ACR ConvergenceDrug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

Thomas R. Collins  |  July 14, 2015

CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…

Filed under:ConditionsDrug UpdatesEducation & TrainingMeeting ReportsProfessional TopicsResearch RheumSystemic Lupus Erythematosus Tagged with:AC&Rclinical symposiumJAK inhibitorLupusOsteoarthritisoutcomepatient careResearchTreatment

Clinical Rheumatology Year in Review 2021

Samantha C. Shapiro, MD  |  November 22, 2021

ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersResearch RheumRheumatoid ArthritisVasculitis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAClinicalClinical researchJAK inhibitorsjakinibsJanus Kinase InhibitorsKnee Osteoarthritis (OA)stepped exercise

From Contraception to Breastfeeding: Experts Address Reproductive Health & Medication Management

Mithu Maheswaranathan, MD  |  November 11, 2021

ACR CONVERGENCE 2021—Rheumatologists are often left in a challenging space when managing medications for patients with rheumatic diseases in relation to contraception, pregnancy and breastfeeding, especially with many novel immunosuppressants and often a dearth of pregnancy safety data. On Nov. 6 during ACR Convergence 2021, leading reproductive health experts came together to speak on this…

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2021breastfeedingcontraceptivepregnancyreproductive health

Summer 2021’s Awards, Appointments & Announcements in Rheumatology

Kelly April Tyrrell & Gretchen Henkel  |  September 14, 2021

Marian Hannan Celebrated after 10 Years as AC&R Editor-in-Chief By Kelly April Tyrrell This summer, the 10-year tenure of Marian Hannan, MPH, DSc, as editor in chief of Arthritis Care & Research (AC&R), has come to an end. Kelli Allen, PhD, assumed the post on July 1. “Marian has done a fantastic job over the…

Filed under:AwardsProfiles Tagged with:Dr. John J. O’SheaDr. Marian HannanDr. Tuhina Neogi

Case Report: A 5-Year-Old with an Ischemic Digit

Marta Michalska-Smith, MD, & Colleen K. Correll, MD, MPH  |  September 14, 2021

Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…

Filed under:Conditions Tagged with:Aicardi-Goutières SyndromeJanus Kinase Inhibitors

FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

Keri Losavio  |  September 1, 2021

On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…

Filed under:Drug Updates Tagged with:baricitinibJAK inhibitorsjakinibsTofacitinibupadacitinib

20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends

Michele B. Kaufman, PharmD, BCGP  |  September 1, 2021

Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:biologic drugsEULARRheumatoid Arthritis (RA)trends

Janus Kinase Inhibitors Promising for Difficult-to-Treat RA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

In a study, Janus kinase inhibitors proved effective for patients with difficult-to-treat rheumatoid arthritis (RA).

Filed under:Drug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:baricitinibEULARJAK inhibitorjakinibJanus Kinase InhibitorsRheumatoid Arthritis (RA)Tofacitinib

  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences